Cargando…

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma

Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial growth factor, has been widely used as a first‐line treatment against metastatic renal cell carcinoma (mRCC). However, mRCC often acquires resistance to sunitinib, rendering it difficult to treat with this a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuroshima, Kazuki, Yoshino, Hirofumi, Okamura, Shunsuke, Tsuruda, Masafumi, Osako, Yoichi, Sakaguchi, Takashi, Sugita, Satoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226215/ https://www.ncbi.nlm.nih.gov/pubmed/32232883 http://dx.doi.org/10.1111/cas.14395

Ejemplares similares

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant
por: Tsuruda, Masafumi, et al.
Publicado: (2020)

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
por: Okamura, Shunsuke, et al.
Publicado: (2021)

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1
por: Tamai, Motoki, et al.
Publicado: (2022)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2017)

Potential therapeutic target secretogranin II might cooperate with hypoxia‐inducible factor 1α in sunitinib‐resistant renal cell carcinoma
por: Fukumoto, Wataru, et al.
Publicado: (2023)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery
por: Tatarano, Shuichi, et al.
Publicado: (2021)

Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients
por: Tatarano, Shuichi, et al.
Publicado: (2022)

Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients
por: Mitsuke, Akihiko, et al.
Publicado: (2023)

microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2017)

Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines
por: TATARANO, SHUICHI, et al.
Publicado: (2011)

Kidney transplantation with concomitant simple nephrectomy by thoracoabdominal approach for patients with huge autosomal dominant polycystic kidney disease (ADPKD): A case report
por: Yamada, Yasutoshi, et al.
Publicado: (2019)

mTOR Inhibitor Rapalink-1 Prevents Ethanol-Induced Senescence in Endothelial Cells
por: Zhou, Huakang, et al.
Publicado: (2023)

The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
por: Yoshino, H, et al.
Publicado: (2011)

Rapalink-1 Increased Infarct Size in Early Cerebral Ischemia–Reperfusion With Increased Blood–Brain Barrier Disruption
por: Chi, Oak Z., et al.
Publicado: (2021)

The role of microRNAs in bladder cancer
por: Enokida, Hideki, et al.
Publicado: (2016)

Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide
por: Vargas-Toscano, Andres, et al.
Publicado: (2020)

Commentary: Rapalink-1 Increased Infarct Size in Early Cerebral Ischemia–Reperfusion With Increased Blood–Brain Barrier Disruption
por: Beard, Daniel J., et al.
Publicado: (2021)

Antiangiogenic Therapy Using Sunitinib Combined with Rapamycin Retards Tumor Growth But Promotes Metastasis()
por: Yin, Tao, et al.
Publicado: (2014)

Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
por: La Manna, Federico, et al.
Publicado: (2020)

New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma
por: Agulnik, Mark
Publicado: (2012)

Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
por: La Manna, Federico, et al.
Publicado: (2021)

Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors
por: Tamada, Satoshi, et al.
Publicado: (2018)

LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
por: Matsuda, R, et al.
Publicado: (2011)

Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer
por: CHIYOMARU, TAKESHI, et al.
Publicado: (2014)

Dual tumor‐suppressors miR‐139‐5p and miR‐139‐3p targeting matrix metalloprotease 11 in bladder cancer
por: Yonemori, Masaya, et al.
Publicado: (2016)

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
por: Chan, S
Publicado: (2004)

New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
por: Carraway, Hetty, et al.
Publicado: (2004)

miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
por: Chiyomaru, T, et al.
Publicado: (2010)

Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report
por: Nishimura, Hiroaki, et al.
Publicado: (2018)

Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer
por: Yamaguchi, Hiroyuki, et al.
Publicado: (2015)

Rapamycin-inspired macrocycles with new target specificity
por: Guo, Zufeng, et al.
Publicado: (2018)

l-Tryptophan-mediated Enhancement of Susceptibility to Nonalcoholic Fatty Liver Disease Is Dependent on the Mammalian Target of Rapamycin
por: Osawa, Yosuke, et al.
Publicado: (2011)

Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer
por: Matsushita, R, et al.
Publicado: (2015)

Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist
por: Gole, Prachi, et al.
Publicado: (2014)

Mammalian Target of Rapamycin Inhibitors and Wound Healing Complications in Kidney Transplantation: Old Myths and New Realities
por: Mabood Khalil, Muhammad Abdul, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ki2s6h28o1e3kv4smtr1bqgu9v